NRX Pharmaceuticals, Inc.

SEC insider activity covers quarterly filings through June 30, 2026. Later filings are not included. Reported roles do not establish current employment or current holdings. SEC filing documents, sections and filing-text search cover filings dated January 1, 2000 onward. Earlier filings are deferred until after launch.

NRXP

organization

SIC: 2834

SEC Insider

$11.4M

107 transactions

Summary

NRX Pharmaceuticals, Inc. (NRXP) is an organization.

Recent Insider Transactions

As filed, including amendments; not net cash flow or current holdings. Joint reports count once. Totals cover known values only.

Buys: $7.5MSales: $3.0M20 insiders

Date	Insider	Type	Value
2022-12-07	Javitt Jonathan C	Sell	$400K
2023-08-22	Javitt Jonathan C(Chief Scientist)	Buy	$64K
2022-12-16	Willard Stephen H(CHIEF EXECUTIVE OFFICER)	Buy	$59K
2024-12-17	Javitt Jonathan C(Chairman and Chief Scientist)	Buy	$47K
2023-08-23	Javitt Jonathan C(Chief Scientist)	Buy	$33K
2022-12-16	VAN VOORHEES SETH(CHIEF FINANCIAL OFFICER)	Buy	$33K
2022-11-29	Javitt Daniel C.	Sell	$21K
2023-08-30	Hurvitz Chaim	Buy	$20K
2022-11-30	Javitt Daniel C.	Sell	$13K
2023-08-30	Gorovitz Aaron	Buy	$11K
2022-11-28	Flynn Patrick John	Buy	$3K
2022-11-28	Flynn Patrick John	Buy	$3K
2022-11-28	Flynn Patrick John	Buy	$3K
2026-01-27	Casper Joseph Michael(Chief Operating Officer)	A	$0
2025-04-09	Flynn Patrick John	A	$0
2025-04-09	Hurvitz Chaim	A	$0
2025-04-09	McBride Dennis	A	$0
2025-04-09	Javitt Jonathan C(Chairman and Chief Scientist)	A	$0
2025-02-07	ABRAMS MICHAEL S(Chief Financial Officer)	A	$0
2022-12-14	Javitt Jonathan C	G	$0

SEC filings: SEC EDGAR

Activity data: SEC EDGAR

NRX Pharmaceuticals, Inc. — Contributions, Lobbying & Contracts | Poliscope